Jeffrey Settleman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8889810/publications.pdf

Version: 2024-02-01

1163117 1474206 2,911 10 8 9 citations g-index h-index papers 11 11 11 6669 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Reports, 2019, 29, 118-134.e8.	6.4	63
2	Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. ELife, $2019,8,.$	6.0	69
3	Challenges in validating candidate therapeutic targets in cancer. ELife, 2018, 7, .	6.0	25
4	Regulation of autophagy, NF- \hat{l}^0 B signaling, and cell viability by miR-124 in <i>KRAS</i> mutant mesenchymal-like NSCLC cells. Science Signaling, 2017, 10, .	3.6	21
5	A three-drug combination to treat BRAF-mutant cancers. Nature Medicine, 2017, 23, 913-914.	30.7	6
6	TORquing metabolic reprogramming in cancer cells. Cell Cycle, 2016, 15, 2387-2388.	2.6	1
7	Communication in Drug Development: "Translating―Scientific Discovery. Cell, 2016, 164, 1101-1104.	28.9	11
8	Bet on drug resistance. Nature, 2016, 529, 289-290.	27.8	34
9	Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 2012, 483, 570-575.	27.8	2,173
10	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer, 2010, 10, 241-253.	28.4	506